Skip to main content

Prototype Prescribing Outlier Dashboard for Heaton Moor Medical Group

At OpenPrescribing we are piloting a number of data-driven approaches to identify unusual prescribing and collect feedback on this prescribing to inform development of new tools to support prescribers and organisations to audit and review prescribing. These pilot results are provided for the interest of advanced users, although we don't know how relevant they are in practice. There is substantial variation in prescribing behaviours, across various different areas of medicine. Some variation can be explained by demographic changes, or local policies or guidelines, but much of the remaining variation is less easy to explain.

The DataLab is keen to hear your feedback on the results. You can do this by completing the following survey or emailing us at [email protected]. Please DO NOT INCLUDE IDENTIFIABLE PATIENT information in your feedback. All feedback is helpful, you can send short or detailed feedback.

This report has been developed to automatically identify prescribing patterns at a chemical level which are furthest away from “typical prescribing” and can be classified as an “outlier”. We calculate the number of prescriptions for each chemical in the BNF coding system, the count of all prescriptions within that chemical's BNF subparagraph, for prescriptions dispensed between June 2021 and December 2021. We then calculate the ratio of these counts along with the mean and standard deviation of those ratios across all Practices. From this we can calculate the “z-score”, which is a measure of how many standard deviations a given Practice is from the population mean. We then rank your “z-scores” to find the top 10 results where prescribing is an outlier for prescribing higher than its peers and those where it is an outlier for prescribing lower than its peers.

For each outlier chemical, a kernel density estimation plot of all Practice's chemical:subparagraph ratios is provided, with this Practice's ratio overlaid in red.

It is important to remember that this information was generated automatically and it is therefore likely that some of the behaviour is warranted. This report seeks only to collect information about where this variation may be warranted and where it might not, to inform research on this topic. Our full analytical method code is openly available on GitHub here.

This is a new, experimental feature. We'd love to .

Prescribing where Heaton Moor Medical Group is higher than most

BNF Chemical Chemical Items BNF Subparagraph Subparagraph Items Ratio Mean std Z_Score Plots
Chloroquine phosphate 16 Antimalarials 757 0.02 0.00 0.00 4.33
Semaglutide 1,350 Other antidiabetic drugs 6,931 0.19 0.05 0.05 2.83
Flubiprofen 13 Drugs for oral ulceration and inflammation 419 0.03 0.00 0.01 2.60
Other otitis external preparations 1 Otitis externa 775 0.00 0.00 0.00 2.45
Nicardipine hydrochloride 40 Calcium-channel blockers 18,090 0.00 0.00 0.00 2.23
Ketone blood testing reagents 319 Diabetic diagnostic and monitoring agents 2,838 0.11 0.05 0.03 2.18
Methotrexate 86 Antimetabolites 94 0.91 0.20 0.35 2.08
Trospium chloride 461 Drugs for urinary frequency enuresis and incontinence 3,813 0.12 0.04 0.04 1.96
Acebutolol hydrochloride 25 Beta-adrenoceptor blocking drugs 19,793 0.00 0.00 0.00 1.96
Timolol 385 Treatment of glaucoma 3,236 0.12 0.06 0.03 1.91

Prescribing where Heaton Moor Medical Group is lower than most

BNF Chemical Chemical Items BNF Subparagraph Subparagraph Items Ratio Mean std Z_Score Plots
Mercaptopurine 8 Antimetabolites 94 0.09 0.80 0.35 -2.07
Gliclazide 1,299 Sulfonylureas 1,888 0.69 0.93 0.13 -1.77
Losartan potassium 1,593 Angiotensin-II receptor antagonists 8,616 0.18 0.50 0.19 -1.70
Glucose blood testing reagents 2,511 Diabetic diagnostic and monitoring agents 2,838 0.88 0.94 0.03 -1.70
Sodium picosulfate 1 Bowel cleansing preparations 8 0.12 0.69 0.43 -1.32
Solifenacin 700 Drugs for urinary frequency enuresis and incontinence 3,813 0.18 0.33 0.11 -1.31
Nicorandil 488 Other antianginal drugs 2,071 0.24 0.50 0.20 -1.29
Biphasic insulin aspart 58 Intermediate and long-acting insulins 1,983 0.03 0.14 0.09 -1.29
Hydrocortisone 158 Copound haemorrhoidal preparations with corticosteroid 612 0.26 0.57 0.24 -1.28
Famotidine 430 H2-Receptor antagonists 783 0.55 0.81 0.21 -1.25